Zhongtai Securities: Pharma Supply Chain Momentum Persists, AI4S Expected to Drive Further Valuation Re-rating

Stock News11-12

Zhitong Finance App has learned that Zhongtai Securities Co.,Ltd. (600918) released a research report stating that in the first three quarters of 2026, multiple CRO and CDMO companies have deployed AI. For example, WuXi AppTec's testing business is accelerating the integration of "HI+AI" to meet the rapidly growing demand for dry-wet closed-loop services from global AI4S clients, and Joinn Laboratories' AI pathology image reading and organoid platforms are extending toward the front end of drug discovery, with the increase in AI candidate molecules directly driving safety assessment demand. It is expected that as AIDD projects continue to extend toward the back end, this is likely to bring strong growth momentum to the sector in the medium to long term. 2026Q3 continued strong growth, demand remains robust, and AI4S is expected to drive further valuation re-rating: 1) 2026Q3 showed a trend of sustained improvement: 2026Q1-Q3 revenue for key CRO and CDMO sector targets rose 21.8%, net profit attributable to parent rose 36.3%, and non-GAAP net profit rose 53.6%. By quarter, 2026Q3 revenue rose 24.9%, net profit attributable to parent rose 84.5%, and non-GAAP net profit rose 44.8%, showing a trend of sustained rapid growth. 2) Demand remains strong: in 2026, orders at CRO and CDMO companies continued to grow rapidly. For example, WuXi AppTec's backlog for continuing operations in 2026Q1-Q3 rose 36.4% year over year, Pharmaron's newly signed orders rose 30% year over year, Joinn Laboratories' cumulative newly signed orders rose 109% year over year, and Innostellar rose 183.27% year over year. 3) The supply side has returned to an expansion cycle: in 2026Q1-Q3, sector fixed assets rose 6.9% and construction in progress rose 12.9%. Zhongtai Securities expects this was mainly due to continued recovery in demand, with industry capacity gradually tightening. 4) AI4S: in the first three quarters of 2026, multiple CRO and CDMO companies deployed AI. For example, WuXi AppTec's testing business is accelerating the integration of "HI+AI" to meet the rapidly growing demand for dry-wet closed-loop services from global AI4S clients, and Joinn Laboratories' AI pathology image reading and organoid platforms are extending toward the front end of drug discovery, with the increase in AI candidate molecules directly driving safety assessment demand. Zhongtai Securities expects that as AIDD projects continue to extend toward the back end, this is likely to bring strong growth momentum to the sector in the medium to long term. 5) Profitability: gross margin and net margin both moved steadily upward. In 2026Q1-Q3, the sector's overall gross margin was approximately 43.6% (+4.2pp), and net margin was approximately 25.0% (+2.7pp). Investment recommendation: supply chain momentum persists, AI4S is expected to drive further valuation re-rating, and investors should actively capture the new round of R&D and production expansion cycle: 1) CRO: ① Since 2024, although overseas monthly CPI data has fluctuated, expectations for improved investment and financing are likely to improve at the margin, and order recovery has already been seen at some companies. Coupled with the gradual acceleration of AI4S demand, Zhongtai Securities expects overseas-demand CROs to usher in a Davis double-play opportunity in earnings and valuation, and recommends close attention; ② the clinical CRO sector is benefiting from domestic innovative drug policy support and an improved financing environment, and the sector's reversal trend is likely to continue, so continued close attention is recommended; ③ as domestic innovative drugs remain vibrant, domestic preclinical CRO orders continue to grow rapidly, and subsequent business is expected to gradually materialize, so investors are advised to actively seize opportunities. 2) CDMO: driven by continued downstream technological breakthroughs and a new round of commercialization landing for chemical drugs, demand for development and production of peptide, oligonucleotide, XDC, and bispecific antibody CDMO services is expected to rise rapidly, and investors should continue to monitor investment opportunities across the related supply chain.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment